Posted:
Gallaudet University, in Washington, D.C, released an institutional position statement addressing gene editing and gene therapy for deafness. The statement, developed by a university think tank, affirms that deaf people are an essential part of human diversity and calls for deaf families, communities, scientists, and scholars to be central to decisions about these technologies.
The statement responds to recent scientific developments, including the FDA’s April 2026 approval of the first gene therapy for a rare hereditary form of deafness linked to the OTOF gene, and the first treatment of a child in an August 2026 clinical trial targeting GJB2, the most common genetic cause of deafness in North America and Europe. Gallaudet’s president, Roberta Cordano, framed the position not as opposition to gene therapy, but as a call for experiences to help shape how these technologies develop, how they are funded, and how families make decisions. University faculty noted the long history of efforts to “fix” or “cure” deafness and emphasized that deaf people are not a problem to be solved.
This is a university’s position statement, reflecting a range of views within deaf communities rather than a single settled position. Gene therapies for genetic deafness remain early in their development and apply only to specific genetic causes.
Learn more here.


